{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:20:33Z","timestamp":1770740433059,"version":"3.49.0"},"reference-count":17,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,12,13]],"date-time":"2015-12-13T00:00:00Z","timestamp":1449964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Chinese Medical Doctor Association Sunshine Cardiovascular Research Foundation","award":["SCRFCMDA201312"],"award-info":[{"award-number":["SCRFCMDA201312"]}]},{"name":"Research Foundation of the Second Hospital of Tianjin Medical University","award":["Y1002"],"award-info":[{"award-number":["Y1002"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Pharma Physio"],"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Patients with complex coronary lesions undergoing percutaneous coronary intervention (<jats:styled-content style=\"fixed-case\">PCI<\/jats:styled-content>) have more major adverse cardiac events (<jats:styled-content style=\"fixed-case\">MACE<\/jats:styled-content>) than do those with simpler cases. Therefore, intensive antiplatelet therapy might be needed in these patients. A total of 127 patients with complex lesions undergoing <jats:styled-content style=\"fixed-case\">PCI<\/jats:styled-content> in the Second Hospital of Tianjin Medical University from October 2012 to April 2014 were randomized to receive either dual (aspirin plus clopidogrel, <jats:styled-content style=\"fixed-case\">DAPT<\/jats:styled-content>,<jats:italic> n<\/jats:italic>\u00a0=\u00a066), or triple antiplatelet therapy (aspirin plus clopidogrel plus cilostazol; <jats:styled-content style=\"fixed-case\">TAPT<\/jats:styled-content>,<jats:italic> n<\/jats:italic>\u00a0=\u00a061). Patients in the <jats:styled-content style=\"fixed-case\">TAPT<\/jats:styled-content> group received low\u2010dose cilostazol (100\u00a0mg loading, followed with 50\u00a0mg twice per day) for 3\u20136\u00a0months. The primary endpoint was composite <jats:styled-content style=\"fixed-case\">MACE<\/jats:styled-content>. The complex coronary target lesions were defined as at least one of the following: left main disease; severe 3\u2010vessel disease; chronic total occlusion lesions; true bifurcation lesion; ostial lesions; severe calcified lesions; and highly thrombotic lesions. The two groups had similar baseline clinical and angiographic characteristics. One\u2010year clinical outcomes showed that the <jats:styled-content style=\"fixed-case\">TAPT<\/jats:styled-content> group had significantly lower incidences of myocardial infarction (1.6% <jats:italic>vs<\/jats:italic> 13.6%, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.018) and <jats:styled-content style=\"fixed-case\">MACE<\/jats:styled-content> (1.6% <jats:italic>vs<\/jats:italic> 16.7%, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.004) than <jats:styled-content style=\"fixed-case\">DAPT<\/jats:styled-content> group. The <jats:styled-content style=\"fixed-case\">DAPT<\/jats:styled-content> group had two cases of stent thrombosis, while the <jats:styled-content style=\"fixed-case\">TAPT<\/jats:styled-content> group did not. Furthermore, adjunctive low\u2010dose cilostazol didn't significantly increase the incidence of bleeding events (26.2% <jats:italic>vs<\/jats:italic> 19.7%, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.381) regardless of major (4.9% <jats:italic>vs<\/jats:italic> 4.5%, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.921) or minor (21.3% <jats:italic>vs<\/jats:italic> 15.2%, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.368) bleeding events. In conclusion, low\u2010dose adjunctive cilostazol seems superior to dual antiplatelet therapy in reducing recurrent ischemic events in patients with complex coronary lesions and the two test groups have a similar incidence of bleeding events.<\/jats:p>","DOI":"10.1111\/1440-1681.12495","type":"journal-article","created":{"date-parts":[[2015,9,28]],"date-time":"2015-09-28T21:08:40Z","timestamp":1443474520000},"page":"29-33","source":"Crossref","is-referenced-by-count":9,"title":["Low\u2010dose adjunctive cilostazol in patients with complex lesions undergoing percutaneous coronary intervention"],"prefix":"10.1111","volume":"43","author":[{"given":"Xin\u2010Tian","family":"Zheng","sequence":"first","affiliation":[{"name":"Tianjin Key Laboratory of Ionic\u2010Molecular Function of Cardiovascular Disease Department of Cardiology Tianjin Institute of Cardiology Second Hospital of Tianjin Medical University Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang\u2010Yin","family":"Chen","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Ionic\u2010Molecular Function of Cardiovascular Disease Department of Cardiology Tianjin Institute of Cardiology Second Hospital of Tianjin Medical University Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Liu","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Ionic\u2010Molecular Function of Cardiovascular Disease Department of Cardiology Tianjin Institute of Cardiology Second Hospital of Tianjin Medical University Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling\u2010Xia","family":"Xu","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Ionic\u2010Molecular Function of Cardiovascular Disease Department of Cardiology Tianjin Institute of Cardiology Second Hospital of Tianjin Medical University Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing\u2010Jin","family":"Che","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Ionic\u2010Molecular Function of Cardiovascular Disease Department of Cardiology Tianjin Institute of Cardiology Second Hospital of Tianjin Medical University Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung\u2010Woon","family":"Rha","sequence":"additional","affiliation":[{"name":"Cardiovascular Centre Korea University Guro Hospital Seoul Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang\u2010Ping","family":"Li","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Ionic\u2010Molecular Function of Cardiovascular Disease Department of Cardiology Tianjin Institute of Cardiology Second Hospital of Tianjin Medical University Tianjin China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,12,13]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.06.047"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.009985"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2014.06.014"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.850067"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.822791"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/1074248412468944"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.11.049"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.10.035"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2013.08.008"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2009.01.006"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.5551\/jat.25577"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s102380300004"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2003.08.017"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.621359"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31823ba622"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2011.03.001"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2009.12.041"}],"container-title":["Clinical and Experimental Pharmacology and Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1440-1681.12495","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1440-1681.12495","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T02:08:14Z","timestamp":1696298894000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1440-1681.12495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,13]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.1111\/1440-1681.12495"],"URL":"https:\/\/doi.org\/10.1111\/1440-1681.12495","archive":["Portico"],"relation":{},"ISSN":["0305-1870","1440-1681"],"issn-type":[{"value":"0305-1870","type":"print"},{"value":"1440-1681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,13]]}}}